ScripRegeneron is acquiring a dual GIP/GLP-1 agonist – a similar product to Eli Lilly’s blockbuster tirzepatide – to develop proprietary combinations that could deliver similar or even better weight loss b
Pink SheetEli Lilly and Novo Nordisk may be considering big US price reductions for GLP-1 drugs for obesity and diabetes, at least partly in response to President Trump’s recent executive order on Most Fav
ScripSV Health Investors announced the final closing for its second Dementia Discovery Fund, DDF-2, with $269m in commitments from investors and non-profit organizations willing to put their money behind s
In VivoA study by precision obesity medicine biotech Phenomix Sciences and researchers at the Mayo Clinic found that a machine learning-assisted genetic risk score can predict which patients are more likely